JP2023531493A - Il-10突然変異タンパク質及びその融合タンパク質 - Google Patents

Il-10突然変異タンパク質及びその融合タンパク質 Download PDF

Info

Publication number
JP2023531493A
JP2023531493A JP2022578995A JP2022578995A JP2023531493A JP 2023531493 A JP2023531493 A JP 2023531493A JP 2022578995 A JP2022578995 A JP 2022578995A JP 2022578995 A JP2022578995 A JP 2022578995A JP 2023531493 A JP2023531493 A JP 2023531493A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022578995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531493A5 (cg-RX-API-DMAC7.html
Inventor
スー,ハイリン
フォルツ,イアン
モック,マリッサ
ルナ,ビクター・ミッチ
ジャン,ミン
ワンバーグ,シャロン
カンデア・タピア,ガムゼ・オズレム
ライリー,ティモシー・ピー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2023531493A publication Critical patent/JP2023531493A/ja
Publication of JP2023531493A5 publication Critical patent/JP2023531493A5/ja
Priority to JP2026069044A priority Critical patent/JP2026123093A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022578995A 2020-06-26 2021-06-25 Il-10突然変異タンパク質及びその融合タンパク質 Withdrawn JP2023531493A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026069044A JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063045041P 2020-06-26 2020-06-26
US63/045,041 2020-06-26
US202063199218P 2020-12-14 2020-12-14
US63/199,218 2020-12-14
PCT/US2021/039191 WO2021263167A2 (en) 2020-06-26 2021-06-25 Il-10 muteins and fusion proteins thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026069044A Division JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Publications (2)

Publication Number Publication Date
JP2023531493A true JP2023531493A (ja) 2023-07-24
JP2023531493A5 JP2023531493A5 (cg-RX-API-DMAC7.html) 2024-06-19

Family

ID=77071744

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022578995A Withdrawn JP2023531493A (ja) 2020-06-26 2021-06-25 Il-10突然変異タンパク質及びその融合タンパク質
JP2026069044A Pending JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026069044A Pending JP2026123093A (ja) 2020-06-26 2026-04-17 Il-10突然変異タンパク質及びその融合タンパク質

Country Status (17)

Country Link
US (1) US12630598B2 (cg-RX-API-DMAC7.html)
EP (1) EP4172184A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023531493A (cg-RX-API-DMAC7.html)
KR (1) KR20230027300A (cg-RX-API-DMAC7.html)
CN (1) CN116209459A (cg-RX-API-DMAC7.html)
AU (1) AU2021296917A1 (cg-RX-API-DMAC7.html)
CA (1) CA3187576A1 (cg-RX-API-DMAC7.html)
CL (3) CL2022003755A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000431A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230025A (cg-RX-API-DMAC7.html)
IL (2) IL330191A (cg-RX-API-DMAC7.html)
JO (1) JOP20220348A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022016548A (cg-RX-API-DMAC7.html)
PE (1) PE20231082A1 (cg-RX-API-DMAC7.html)
TW (1) TW202216743A (cg-RX-API-DMAC7.html)
UY (1) UY39298A (cg-RX-API-DMAC7.html)
WO (1) WO2021263167A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024131600A1 (zh) * 2022-12-24 2024-06-27 广东菲鹏制药股份有限公司 Il10突变体、融合蛋白和药物
CN116425857B (zh) * 2023-06-09 2023-08-18 苏州依科赛生物科技股份有限公司 一种无糖基化修饰的il-15及制备方法
CN117143235B (zh) * 2023-10-26 2024-02-09 中国科学院苏州纳米技术与纳米仿生研究所 一种单克隆抗体及应用
CN121108363A (zh) * 2024-06-12 2025-12-12 广东菲鹏制药股份有限公司 一种融合蛋白及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
DE19851675A1 (de) 1998-11-10 2000-05-11 Bayer Ag Menschliche Interleukin-10 Mutantenproteine
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
AU2001231532A1 (en) 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2004044006A1 (en) * 2002-11-14 2004-05-27 Maxygen, Inc. Conjugates of interleukin-10 and polymers
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
DE602006011311D1 (de) 2005-05-31 2010-02-04 Univ Colorado Il-10 mutante
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー/エス 骨髄細胞で発現されるトリガー受容体1(trem−1)に結合し、それを遮断する抗体
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
MX385794B (es) 2012-09-07 2025-03-18 Inst Nat Sante Rech Med Péptidos inhibidores obtenidos del receptor desencadenante expresado en células mieloides de tipo 1 (trem-1) y transcrito similar a trem 1 (tlt-1) y usos de los mismos.
SI3021873T1 (sl) * 2013-07-18 2018-12-31 Xalud Therapeutics, Inc. Sestavek za zdravljenje vnetne sklepne bolezni
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
JP7023853B2 (ja) 2016-03-04 2022-02-22 アレクトル エルエルシー 抗trem1抗体及びその使用方法
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
CR20250022A (es) 2018-04-02 2025-02-25 Bristol Myers Squibb Co Anticuerpos anti-trem-1, ácidos nucleicos y vectores de los mismos (divisional 2020-0450)
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス,インコーポレイテッド インターロイキン-10ポリペプチド複合体、その二量体、およびそれらの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160068583A1 (en) * 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 18, JPN6025023632, 2000, pages 13552 - 13557, ISSN: 0005770337 *

Also Published As

Publication number Publication date
WO2021263167A3 (en) 2022-04-21
UY39298A (es) 2022-01-31
WO2021263167A2 (en) 2021-12-30
US20230265145A1 (en) 2023-08-24
EP4172184A2 (en) 2023-05-03
JP2026123093A (ja) 2026-07-29
JOP20220348A1 (ar) 2022-12-22
CO2023000431A2 (es) 2023-03-27
AU2021296917A1 (en) 2023-02-02
KR20230027300A (ko) 2023-02-27
CA3187576A1 (en) 2021-12-30
US12630598B2 (en) 2026-05-19
CL2022003755A1 (es) 2023-07-21
CR20230025A (es) 2023-10-05
PE20231082A1 (es) 2023-07-17
TW202216743A (zh) 2022-05-01
CN116209459A (zh) 2023-06-02
CL2024003619A1 (es) 2025-03-14
IL330191A (en) 2026-08-01
IL299149A (en) 2023-02-01
MX2022016548A (es) 2023-03-14
CL2024003618A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
JP7263007B2 (ja) 抗tl1a/抗tnf-アルファ二重特異性抗原結合タンパク質及びその使用
JP6621778B2 (ja) IL7受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
JP6163158B2 (ja) Cd40lに拮抗する抗体ポリペプチド
JP7603205B2 (ja) 抗体分子
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
JP6976322B2 (ja) 新規抗ctla4抗体
US20170304437A1 (en) Bispecific molecules capable of specifically binding to both ctla-4 and cd40
US12630598B2 (en) IL-10 muteins and fusion proteins thereof
TW202132347A (zh) 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
TW202033556A (zh) 拮抗性cd40單株抗體及其用途
AU2016369307A1 (en) Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F
CN105324127B (zh) 对baff和b7rp1具有特异性的蛋白和其用途
TW201039847A (en) Antibodies against human tweak and uses thereof
US20240279332A1 (en) Treatment of Cardiovascular Disease with TREM-1 Antigen Binding Proteins
TW202322846A (zh) 新穎的il27受體促效劑及其使用方法
JP2026081251A (ja) 抗trem-1抗体およびその使用
KR20250050855A (ko) Igf1r 항체
CN117751142A (zh) 用trem-1抗原结合蛋白治疗心血管疾病
JP7525397B2 (ja) ネコMcDonough肉腫(FMS)様チロシンキナーゼ3受容体リガンド(FLT3L)に対する抗体並びに自己免疫疾患及び炎症性疾患を治療するためのそれらの使用
TW202144425A (zh) 特異性抗原結合分子,其製備方法及醫藥用途
EA051986B1 (ru) Антигенсвязывающий белок и слитый белок, его содержащий
JP6529602B2 (ja) 抗cd20/抗baff二重特異性抗体
AU2021331087A1 (en) Method of treating an autoimmune disease with antagonistic CD40 monoclonal antibodies
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
BR122025021892A2 (pt) Células hospedeiras

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260518